<!doctype html><html lang=en-us dir=ltr><head><meta charset=utf-8><meta name=viewport content="width=device-width,initial-scale=1"><meta name=description content="The Court of Appeal pawing at a combination SPC this holiday
season &amp;hellip;
It is the most wonderful time of the year.Â Or, so they say. If you haven&amp;rsquo;t been able to enjoy the glittering lights illuminating London, feast upon the myriad of Christmas markets around Europe or have an unexpected snowball fight in Central Park, there is still some Christmas cheer to bring you to your desk.Â That is, if you like SPC law."><title>BREAKING: Court of Appeal frames Article 3(a) test as one of "claim requirement", but still upholds Truvada SPC invalidity</title><link rel=canonical href=https://Nexus-Security.github.io/posts/2016-09-09-breaking-court-of-appeal-frames-article/><link rel=stylesheet href=/scss/style.min.7dbfdd4b0c439bdacf631096fda79b869b5850a9d35a3f67b9a557f3010f3972.css><meta property="og:title" content="BREAKING:  Court of Appeal frames Article 3(a) test as one of &#34;claim requirement&#34;, but still upholds Truvada SPC invalidity "><meta property="og:description" content="The Court of Appeal pawing at a combination SPC this holiday
season &amp;hellip;
It is the most wonderful time of the year.Â Or, so they say. If you haven&amp;rsquo;t been able to enjoy the glittering lights illuminating London, feast upon the myriad of Christmas markets around Europe or have an unexpected snowball fight in Central Park, there is still some Christmas cheer to bring you to your desk.Â That is, if you like SPC law."><meta property="og:url" content="https://Nexus-Security.github.io/posts/2016-09-09-breaking-court-of-appeal-frames-article/"><meta property="og:site_name" content="0x000216"><meta property="og:type" content="article"><meta property="article:section" content="Posts"><meta property="article:published_time" content="2019-12-19T18:22:00+01:00"><meta property="article:modified_time" content="2019-12-19T18:22:00+01:00"><meta name=twitter:title content="BREAKING:  Court of Appeal frames Article 3(a) test as one of &#34;claim requirement&#34;, but still upholds Truvada SPC invalidity "><meta name=twitter:description content="The Court of Appeal pawing at a combination SPC this holiday
season &amp;hellip;
It is the most wonderful time of the year.Â Or, so they say. If you haven&amp;rsquo;t been able to enjoy the glittering lights illuminating London, feast upon the myriad of Christmas markets around Europe or have an unexpected snowball fight in Central Park, there is still some Christmas cheer to bring you to your desk.Â That is, if you like SPC law."></head><body class=article-page><script>(function(){const e="StackColorScheme";localStorage.getItem(e)||localStorage.setItem(e,"light")})()</script><script>(function(){const t="StackColorScheme",e=localStorage.getItem(t),n=window.matchMedia("(prefers-color-scheme: dark)").matches===!0;e=="dark"||e==="auto"&&n?document.documentElement.dataset.scheme="dark":document.documentElement.dataset.scheme="light"})()</script><div class="container main-container flex on-phone--column extended"><aside class="sidebar left-sidebar sticky"><button class="hamburger hamburger--spin" type=button id=toggle-menu aria-label="Toggle Menu">
<span class=hamburger-box><span class=hamburger-inner></span></span></button><header><figure class=site-avatar><a href=/><img src=/img/avatar_hue825486955cd7c56d95e38b4bd2a8e3c_229979_300x0_resize_box_3.png width=300 height=300 class=site-logo loading=lazy alt=Avatar></a></figure><div class=site-meta><h1 class=site-name><a href=/>0x000216</a></h1><h2 class=site-description>Where Do Russian Hackers Store Their Exploits? ğŸ¤“ /ussr/bin/ ğŸ˜‹</h2></div></header><ol class=social-menu><li><a href=https://github.com/Nexus-Security target=_blank title=GitHub><svg width="72" height="72" viewBox="0 0 72 72" xmlns="http://www.w3.org/2000/svg"><g fill="none" fill-rule="evenodd"><path d="M36 72c19.882251.0 36-16.117749 36-36 0-19.882251-16.117749-36-36-36-19.882251 365231026e-23-36 16.117749-36 36C24348735e-22 55.882251 16.117749 72 36 72z" fill="#3e75c3"/><path d="M35.9985 12C22.746 12 12 22.7870921 12 36.096644c0 10.6440272 6.876 19.6751861 16.4145 22.8617681C29.6145 59.1797862 30.0525 58.4358488 30.0525 57.7973276 30.0525 57.2250681 30.0315 55.7100863 30.0195 53.6996482c-6.6765 1.4562499-8.085-3.2302544-8.085-3.2302544-1.0905-2.7829884-2.664-3.5239139-2.664-3.5239139C17.091 45.4500754 19.4355 45.4801943 19.4355 45.4801943c2.4075.1701719 3.675 2.4833051 3.675 2.4833051 2.142 3.6820383 5.6175 2.6188404 6.9855 2.0014024C30.3135 48.4077535 30.9345 47.3460615 31.62 46.7436831 26.2905 46.1352808 20.688 44.0691228 20.688 34.8361671c0-2.6308879.9345-4.781379 2.4705-6.4665327C22.911 27.7597262 22.0875 25.3110578 23.3925 21.9934585c0 0 2.016-.6475568 6.6 2.4697516C31.908 23.9285993 33.96 23.6620468 36.0015 23.6515052 38.04 23.6620468 40.0935 23.9285993 42.0105 24.4632101c4.581-3.1173084 6.5925-2.4697516 6.5925-2.4697516C49.9125 25.3110578 49.089 27.7597262 48.8415 28.3696344 50.3805 30.0547881 51.309 32.2052792 51.309 34.8361671c0 9.2555448-5.6115 11.29309-10.9575 11.8894446.860999999999997.7439374 1.629 2.2137408 1.629 4.4621184C41.9805 54.4089489 41.9505 57.0067059 41.9505 57.7973276 41.9505 58.4418726 42.3825 59.1918338 43.6005 58.9554002 53.13 55.7627944 60 46.7376593 60 36.096644 60 22.7870921 49.254 12 35.9985 12" fill="#fff"/></g></svg></a></li><li><a href=mailto:0x000216@gmail.com target=_blank title=Email><svg id="Layer_1" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" viewBox="0 0 512 512" style="enable-background:new 0 0 512 512"><path style="fill:#e6f3ff" d="M512 105.739v300.522c0 27.715-22.372 50.087-50.087 50.087H50.087C22.372 456.348.0 433.976.0 406.261V105.739c0-.89.0-1.781.111-2.671 1.336-25.6 21.704-45.969 47.304-47.304.89-.111 1.781-.111 2.671-.111h411.826c.89.0 1.892.0 2.783.111 25.489 1.336 45.857 21.704 47.193 47.193C512 103.847 512 104.849 512 105.739z"/><path style="fill:#cfdbe6" d="M464.696 55.763c-.892-.111-1.891-.111-2.783-.111H256v400.696h205.913c27.715.0 50.087-22.372 50.087-50.087V105.739c0-.89.0-1.892-.111-2.783C510.553 77.468 490.184 57.099 464.696 55.763z"/><path style="fill:#ff4b26" d="M511.889 102.957c-1.336-25.489-21.704-45.857-47.193-47.193C382.89 137.569 336.951 183.509 256 264.459 225.291 233.732 77.61 85.958 47.416 55.763c-25.6 1.336-45.969 21.704-47.304 47.304C0 103.958.0 104.849.0 105.739v300.522c0 27.715 22.372 50.087 50.087 50.087h16.696V169.739l165.621 165.51c6.456 6.567 15.026 9.795 23.597 9.795 8.57.0 17.141-3.228 23.597-9.795l165.621-165.621v286.72h16.696c27.715.0 50.087-22.372 50.087-50.087V105.739C512 104.849 512 103.847 511.889 102.957z"/><path style="fill:#d93f21" d="M279.596 335.249l165.621-165.621v286.72h16.696c27.715.0 50.087-22.372 50.087-50.087V105.739c0-.89.0-1.892-.111-2.783-1.336-25.489-21.704-45.857-47.193-47.193C382.891 137.569 336.951 183.509 256 264.459v80.584C264.57 345.043 273.141 341.816 279.596 335.249z"/><g/><g/><g/><g/><g/><g/><g/><g/><g/><g/><g/><g/><g/><g/><g/></svg></a></li><li><a href=https://nexus-security.github.io/index.xml target=_blank title=RSS><svg id="Layer_1" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" viewBox="0 0 512 512" style="enable-background:new 0 0 512 512"><path style="fill:#f78c20" d="M78.333 355.334C35.14 355.334.0 390.474.0 433.667S35.14 512 78.333 512s78.333-35.14 78.333-78.333-35.14-78.333-78.333-78.333z"/><g><path style="fill:#ffa929" d="M78.333 381.445c-28.795.0-52.222 23.427-52.222 52.222s23.427 52.222 52.222 52.222 52.222-23.427 52.222-52.222-23.427-52.222-52.222-52.222z"/><path style="fill:#ffa929" d="M477.918 264.861c-21.843-51.641-53.111-98.019-92.936-137.842-39.824-39.824-86.201-71.093-137.843-92.935C193.669 11.468 136.874.0 78.333.0c-4.807.0-8.704 3.897-8.704 8.704v85.519c0 4.807 3.897 8.704 8.704 8.704 182.37.0 330.74 148.369 330.74 330.74.0 4.807 3.897 8.704 8.704 8.704h85.52c4.807.0 8.704-3.897 8.704-8.704C512 375.126 500.533 318.331 477.918 264.861z"/><path style="fill:#ffa929" d="M78.333 163.853c-4.807.0-8.704 3.897-8.704 8.704v95.74c0 4.807 3.897 8.704 8.704 8.704 86.386.0 156.666 70.281 156.666 156.666.0 4.807 3.897 8.704 8.704 8.704h95.74c4.807.0 8.704-3.897 8.704-8.704.0-72.07-28.065-139.826-79.027-190.787-50.961-50.961-118.717-79.027-190.787-79.027z"/></g><g><path style="fill:#f78c20" d="M78.333 242.186c-2.918.0-5.817.076-8.704.206v25.905c0 4.807 3.897 8.704 8.704 8.704 86.386.0 156.666 70.281 156.666 156.666.0 4.807 3.897 8.704 8.704 8.704h25.905c.129-2.886.206-5.786.206-8.704.0-105.752-85.729-191.481-191.481-191.481z"/><path style="fill:#f78c20" d="M78.333 68.113c-2.91.0-5.81.042-8.704.11v26.001c0 4.807 3.897 8.704 8.704 8.704 182.37.0 330.74 148.369 330.74 330.74.0 4.807 3.897 8.704 8.704 8.704h26.001c.067-2.894.11-5.793.11-8.704C443.887 231.777 280.223 68.113 78.333 68.113z"/></g><g/><g/><g/><g/><g/><g/><g/><g/><g/><g/><g/><g/><g/><g/><g/></svg></a></li><li><a href target=_blank title=Slack><svg width="256" height="256" viewBox="0 0 256 256" xmlns="http://www.w3.org/2000/svg" preserveAspectRatio="xMidYMid"><path d="M165.964 15.838c-3.89-11.975-16.752-18.528-28.725-14.636-11.975 3.89-18.528 16.752-14.636 28.725l58.947 181.365c4.048 11.187 16.132 17.473 27.732 14.135 12.1-3.483 19.475-16.334 15.614-28.217L165.964 15.838" fill="#dfa22f"/><path d="M74.626 45.516C70.734 33.542 57.873 26.989 45.9 30.879 33.924 34.77 27.37 47.631 31.263 59.606l58.948 181.366c4.047 11.186 16.132 17.473 27.732 14.132 12.099-3.481 19.474-16.332 15.613-28.217L74.626 45.516" fill="#3cb187"/><path d="M240.162 166.045c11.975-3.89 18.526-16.75 14.636-28.726-3.89-11.973-16.752-18.527-28.725-14.636L44.708 181.632c-11.187 4.046-17.473 16.13-14.135 27.73 3.483 12.099 16.334 19.475 28.217 15.614l181.372-58.93" fill="#ce1e5b"/><path d="M82.508 217.27l43.347-14.084-14.086-43.352-43.35 14.09 14.089 43.347" fill="#392538"/><path d="M173.847 187.591c16.388-5.323 31.62-10.273 43.348-14.084l-14.088-43.36-43.35 14.09 14.09 43.354" fill="#bb242a"/><path d="M210.484 74.706c11.974-3.89 18.527-16.751 14.637-28.727-3.89-11.973-16.752-18.526-28.727-14.636L15.028 90.293C3.842 94.337-2.445 106.422.896 118.022c3.481 12.098 16.332 19.474 28.217 15.613l181.371-58.93" fill="#72c5cd"/><path d="M52.822 125.933c11.805-3.836 27.025-8.782 43.354-14.086-5.323-16.39-10.273-31.622-14.084-43.352l-43.36 14.092 14.09 43.346" fill="#248c73"/><path d="M144.16 96.256l43.356-14.088a546179.21 546179.21.0 00-14.089-43.36L130.07 52.9l14.09 43.356" fill="#62803a"/></svg></a></li><li><a href=https://www.minds.com/0x000216/ target=_blank title=Minds><svg id="Capa_1" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" viewBox="0 0 512 512" style="enable-background:new 0 0 512 512"><g><g><path style="fill:#ffe1b2" d="M256 33.085C245.078 13.38 224.079.0 2e2.0c-23.781.0-45.57 13.293-56.594 34.184C115.711 41.602 96 66.977 96 96c0 .059.0.113.0.172-9.977 7.512-16 19.301-16 31.828.0 1.316.078 2.637.234 3.992C60.211 145.266 48 167.758 48 192c0 14.07 4.039 27.543 11.719 39.262C57.273 236.512 56 242.207 56 248c0 2.738.281 5.445.828 8.098C36.672 267.308 24 288.539 24 312c0 27.973 18.305 52.34 44.109 60.785C65.398 378.828 64 385.324 64 392c0 21.098 13.805 39.508 33.539 45.727C103.891 466.746 129.828 488 160 488c4.617.0 9.227-.512 13.766-1.527C181.992 502 198.141 512 216 512c16.687.0 31.396-8.567 40-21.523V33.085z"/></g><g><g><path style="fill:#ffb980" d="M264 256c-4.422.0-8-3.582-8-8 0-22.055-17.945-40-40-40-8.008.0-15.734 2.355-22.336 6.812-3.023 2.043-7.055 1.781-9.797-.652-3.156-2.809-8.477-6.16-15.867-6.16-4.422.0-8-3.582-8-8s3.578-8 8-8c7.711.0 15.234 2.293 21.719 6.539C197.773 194.246 206.758 192 216 192c30.875.0 56 25.121 56 56C272 252.418 268.422 256 264 256z"/></g></g><g><g><path style="fill:#ffb980" d="M120 120c18.977.0 36.875 7.312 50.414 20.594 3.141 3.09 8.203 3.047 11.312-.109 3.094-3.152 3.047-8.219-.109-11.312C165.07 112.941 143.187 104 120 104c-13.046.0-25.395 2.93-36.542 8.046C81.253 117.019 80 122.423 80 128c0 1.316.078 2.637.234 3.992-.094.062-.173.139-.267.202C91.423 124.501 105.193 120 120 120z"/></g></g><g><g><path style="fill:#ffb980" d="M216 360c0-4.418-3.578-8-8-8s-8 3.582-8 8c0 17.645-14.352 32-32 32-14.211.0-26.82-9.648-30.664-23.465-.703-2.512-2.578-4.523-5.039-5.395-2.453-.871-5.188-.492-7.305 1.02C114.094 371.906 101.305 376 88 376c-6.948.0-13.625-1.149-19.894-3.207-2.214 4.939-3.501 10.19-3.916 15.586C71.714 390.73 79.711 392 88 392c13.297.0 26.187-3.266 37.773-9.52C133.969 397.894 150.141 408 168 408c26.469.0 48-21.531 48-48z"/></g></g><g><path style="fill:#fdc88e" d="M488 312c0-23.461-12.672-44.691-32.828-55.902.547-2.652.828-5.359.828-8.098.0-5.793-1.273-11.488-3.719-16.738C459.961 219.543 464 206.07 464 192c0-24.242-12.211-46.734-32.234-60.008.156-1.355.234-2.676.234-3.992.0-12.527-6.023-24.316-16-31.828.0-.059.0-.113.0-.172.0-29.023-19.711-54.398-47.406-61.816C357.57 13.293 335.781.0 312 0c-24.08.0-45.078 13.38-56 33.085v457.391C264.604 503.433 279.313 512 296 512c17.859.0 34.008-10 42.234-25.527C342.773 487.488 347.383 488 352 488c30.172.0 56.109-21.254 62.461-50.273C434.195 431.508 448 413.097 448 392c0-6.676-1.398-13.172-4.109-19.215C469.695 364.34 488 339.973 488 312z"/></g><g><path style="fill:#f8ab6b" d="M272.008 151.199C272 151.465 272 151.734 272 152c0 26.469 21.531 48 48 48s48-21.531 48-48c0-4.418-3.578-8-8-8s-8 3.582-8 8c0 17.645-14.352 32-32 32s-32-14.355-32-32c0-2.184.219-4.359.656-6.465.492-2.395-.133-4.883-1.703-6.754-1.57-1.871-4.016-3.066-6.352-2.859-.453.012-.891.059-.602.078-13.234.0-24-10.766-24-24v31.813C260.673 147.348 266.061 149.988 272.008 151.199z"/></g><g><path style="fill:#f8ab6b" d="M296 328c9.242.0 18.219-2.246 26.281-6.539C328.765 325.707 336.289 328 344 328c4.422.0 8-3.582 8-8s-3.578-8-8-8c-7.391.0-12.711-3.352-15.867-6.16-2.742-2.434-6.766-2.695-9.797-.656C311.726 309.644 304 312 296 312c-22.055.0-40-17.945-40-40v39.116C266.174 321.517 280.337 328 296 328z"/></g><g><g><path style="fill:#f8ab6b" d="M431.765 131.992c.156-1.355.234-2.676.234-3.992.0-5.577-1.253-10.981-3.458-15.954C417.395 106.93 405.046 104 392 104c-4.422.0-8 3.582-8 8s3.578 8 8 8c14.807.0 28.577 4.501 40.032 12.194C431.939 132.131 431.859 132.054 431.765 131.992z"/></g></g><g><g><path style="fill:#f8ab6b" d="M447.81 388.38c-.415-5.396-1.702-10.647-3.916-15.586C437.624 374.85 430.948 376 424 376c-13.578.0-26.594-4.266-37.641-12.332-2.07-1.5-4.719-1.93-7.133-1.168-2.43.77-4.344 2.648-5.164 5.059C369.101 382.176 355.414 392 340 392c-4.422.0-8 3.582-8 8s3.578 8 8 8c18.875.0 35.961-10.191 45.094-26.156C396.976 388.512 410.258 392 424 392 432.288 392 440.285 390.73 447.81 388.38z"/></g></g></g><g/><g/><g/><g/><g/><g/><g/><g/><g/><g/><g/><g/><g/><g/><g/></svg></a></li><li><a href=https://www.buymeacoffee.com/0x000216 target=_blank title=Coffee><svg id="Capa_1" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" viewBox="0 0 340 340" style="enable-background:new 0 0 340 340"><g id="XMLID_18_"><polygon id="XMLID_138_" style="fill:#dedde0" points="76.429,290 80,340 170,340 170,290"/><polygon id="XMLID_169_" style="fill:#dedde0" points="170,80 61.429,80 65,130 170,130"/><polygon id="XMLID_197_" style="fill:#acabb1" points="170,290 170,340 260,340 263.571,290"/><polygon id="XMLID_221_" style="fill:#acabb1" points="170,80 170,130 275,130 278.571,80"/><path id="XMLID_222_" style="fill:#ffda44" d="M170 260c-22.091.0-40-22.386-40-50s17.909-50 40-50v-30H65 50l10 160h16.429H170V260z"/><path id="XMLID_33_" style="fill:#ff9811" d="M170 130v30c22.091.0 40 22.386 40 50s-17.909 50-40 50v30h93.571H280l10-160h-15H170z"/><path id="XMLID_223_" style="fill:#50412e" d="M210 210c0-27.614-17.909-50-40-50v1e2c22.091.0 40-22.386 40-50z"/><path id="XMLID_224_" style="fill:#786145" d="M130 210c0 27.614 17.909 50 40 50V160c-22.091.0-40 22.386-40 50z"/><polygon id="XMLID_225_" style="fill:#50412e" points="278.571,80 300,80 300,40 260,40 260,0 80,0 80,40 40,40 40,80 61.429,80 170,80"/></g><g/><g/><g/><g/><g/><g/><g/><g/><g/><g/><g/><g/><g/><g/><g/></svg></a></li></ol><ol class=menu id=main-menu><li><a href=/><svg xmlns="http://www.w3.org/2000/svg" class="icon icon-tabler icon-tabler-home" width="24" height="24" viewBox="0 0 24 24" stroke-width="2" stroke="currentcolor" fill="none" stroke-linecap="round" stroke-linejoin="round"><path stroke="none" d="M0 0h24v24H0z"/><polyline points="5 12 3 12 12 3 21 12 19 12"/><path d="M5 12v7a2 2 0 002 2h10a2 2 0 002-2v-7"/><path d="M9 21v-6a2 2 0 012-2h2a2 2 0 012 2v6"/></svg><span>Home</span></a></li><li><a href=/about/><svg xmlns="http://www.w3.org/2000/svg" class="icon icon-tabler icon-tabler-user" width="24" height="24" viewBox="0 0 24 24" stroke-width="2" stroke="currentcolor" fill="none" stroke-linecap="round" stroke-linejoin="round"><path stroke="none" d="M0 0h24v24H0z"/><circle cx="12" cy="7" r="4"/><path d="M6 21v-2a4 4 0 014-4h4a4 4 0 014 4v2"/></svg><span>About Us</span></a></li><li><a href=/termsofservice/><svg xmlns="http://www.w3.org/2000/svg" class="icon icon-tabler icon-tabler-pencil" width="24" height="24" viewBox="0 0 24 24" stroke-width="2" stroke="currentcolor" fill="none" stroke-linecap="round" stroke-linejoin="round"><path stroke="none" d="M0 0h24v24H0z" fill="none"/><path d="M4 20h4L18.5 9.5a1.5 1.5.0 00-4-4L4 16v4"/><line x1="13.5" y1="6.5" x2="17.5" y2="10.5"/></svg><span>Terms Of Service</span></a></li><li><a href=/privacypolicy/><svg xmlns="http://www.w3.org/2000/svg" class="icon icon-tabler icon-tabler-archive" width="24" height="24" viewBox="0 0 24 24" stroke-width="2" stroke="currentcolor" fill="none" stroke-linecap="round" stroke-linejoin="round"><path stroke="none" d="M0 0h24v24H0z"/><rect x="3" y="4" width="18" height="4" rx="2"/><path d="M5 8v10a2 2 0 002 2h10a2 2 0 002-2V8"/><line x1="10" y1="12" x2="14" y2="12"/></svg><span>Privacy Policy</span></a></li><li><a href=/disclaimer/><svg xmlns="http://www.w3.org/2000/svg" class="icon icon-tabler icon-tabler-link" width="24" height="24" viewBox="0 0 24 24" stroke-width="2" stroke="currentcolor" fill="none" stroke-linecap="round" stroke-linejoin="round"><path stroke="none" d="M0 0h24v24H0z"/><path d="M10 14a3.5 3.5.0 005 0l4-4a3.5 3.5.0 00-5-5l-.5.5"/><path d="M14 10a3.5 3.5.0 00-5 0l-4 4a3.5 3.5.0 005 5l.5-.5"/></svg><span>Disclaimer</span></a></li><li><a href=/contact/><svg xmlns="http://www.w3.org/2000/svg" class="icon icon-tabler icon-tabler-mail" width="44" height="44" viewBox="0 0 24 24" stroke-width="1.5" stroke="currentcolor" fill="none" stroke-linecap="round" stroke-linejoin="round"><path stroke="none" d="M0 0h24v24H0z" fill="none"/><rect x="3" y="5" width="18" height="14" rx="2"/><polyline points="3 7 12 13 21 7"/></svg><span>Contact Us</span></a></li><div class=menu-bottom-section><li id=dark-mode-toggle><svg xmlns="http://www.w3.org/2000/svg" class="icon icon-tabler icon-tabler-toggle-left" width="24" height="24" viewBox="0 0 24 24" stroke-width="2" stroke="currentcolor" fill="none" stroke-linecap="round" stroke-linejoin="round"><path stroke="none" d="M0 0h24v24H0z"/><circle cx="8" cy="12" r="2"/><rect x="2" y="6" width="20" height="12" rx="6"/></svg><svg xmlns="http://www.w3.org/2000/svg" class="icon icon-tabler icon-tabler-toggle-right" width="24" height="24" viewBox="0 0 24 24" stroke-width="2" stroke="currentcolor" fill="none" stroke-linecap="round" stroke-linejoin="round"><path stroke="none" d="M0 0h24v24H0z"/><circle cx="16" cy="12" r="2"/><rect x="2" y="6" width="20" height="12" rx="6"/></svg><span>Dark Mode</span></li></div></ol></aside><main class="main full-width"><article class=main-article><header class=article-header><div class=article-details><div class=article-title-wrapper><h2 class=article-title><a href=/posts/2016-09-09-breaking-court-of-appeal-frames-article/>BREAKING: Court of Appeal frames Article 3(a) test as one of "claim requirement", but still upholds Truvada SPC invalidity</a></h2></div><footer class=article-time><div><svg xmlns="http://www.w3.org/2000/svg" class="icon icon-tabler icon-tabler-calendar-time" width="56" height="56" viewBox="0 0 24 24" stroke-width="2" stroke="currentcolor" fill="none" stroke-linecap="round" stroke-linejoin="round"><path stroke="none" d="M0 0h24v24H0z"/><path d="M11.795 21H5a2 2 0 01-2-2V7a2 2 0 012-2h12a2 2 0 012 2v4"/><circle cx="18" cy="18" r="4"/><path d="M15 3v4"/><path d="M7 3v4"/><path d="M3 11h16"/><path d="M18 16.496V18l1 1"/></svg><time class=article-time--published>Dec 19, 2019</time></div><div><svg xmlns="http://www.w3.org/2000/svg" class="icon icon-tabler icon-tabler-clock" width="24" height="24" viewBox="0 0 24 24" stroke-width="2" stroke="currentcolor" fill="none" stroke-linecap="round" stroke-linejoin="round"><path stroke="none" d="M0 0h24v24H0z"/><circle cx="12" cy="12" r="9"/><polyline points="12 7 12 12 15 15"/></svg><time class=article-time--reading>15 minute read</time></div></footer></div></header><section class=article-content><p><a class=link href=https://1.bp.blogspot.com/-HRwXKapoQXs/Xfub0Etr9lI/AAAAAAAAGow/9sKtXtM5__o_zcQXyFFKzfIBCFmumIt2wCLcBGAsYHQ/s1600/cat%2Bchristmas.jpg target=_blank rel=noopener><img src=https://1.bp.blogspot.com/-HRwXKapoQXs/Xfub0Etr9lI/AAAAAAAAGow/9sKtXtM5__o_zcQXyFFKzfIBCFmumIt2wCLcBGAsYHQ/s400/cat%2Bchristmas.jpg loading=lazy></a></p><p><em>The Court of Appeal pawing at a combination SPC this holiday<br>season &mldr;</em></p><p><strong>It is the most wonderful time of the year.Â  Or, so they say.</strong> If you haven&rsquo;t been able to enjoy the glittering lights illuminating London, feast upon the myriad of Christmas markets around Europe or have an unexpected snowball fight in Central Park, there is still some Christmas cheer to bring you to your desk.Â  That is, if you like SPC law.Â </p><p>This morning the Court of Appeal ([2019] EWCA Civ 2272)Â <strong><a class=link href="https://drive.google.com/file/d/0B_U9nV8-MjxrRUhVbGtXUGRoVDhkbzVpR2l2R0g3MGlKOGtz/view?usp=sharing" target=_blank rel=noopener>dismissed Gilead&rsquo;s appeal</a></strong> of Mr Justice Arnold&rsquo;s (as he then was) <a class=link href=https://www.bailii.org/ew/cases/EWHC/Patents/2018/2416.html target=_blank rel=noopener><strong>September 2018 decision</strong></a> in <em>Teva v Gilead</em> finding that Gilead&rsquo;s SPC protecting its combination HIV anti-retroviral drug, <a class=link href="https://www.truvada.com/?utm_medium=cpc&utm_campaign=71700000057762539&utm_content=Truvada_KW&utm_term=Truvada&utm_source=google&&gclid=CjwKCAiA3OzvBRBXEiwALNKDPwtwPxC0rMRZVnZYmFkn1j2ImesmuwHzLIVx7yeXdMaEIghf1OBlWhoC6G0QAvD_BwE&gclsrc=aw.ds" target=_blank rel=noopener><strong>Truvada</strong></a>, was invalid.Â  The product subject to the SPC was a combination of tenofovir disoproxil and emtricitabine.Â  Gilead claimed that this product was protected by Claim 27 of European Patent No 0 915 894 (<strong>the &lsquo;894 Patent</strong>).Â  Teva (and a merry band of other generic companies) argued that the &lsquo;894 Patent did not protect this combination product under Article 3(a) of the <a class=link href="https://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2009:152:0001:0010:en:PDF" target=_blank rel=noopener><strong>SPC Regulation</strong></a>.Â  Article 3(a) requires that an SPC can only be granted if the product subject to the SPC is &ldquo;<em>protected by a basic patent in force&rdquo;</em>.Â Â </p><p><strong>Background</strong></p><p>Back in December 2016, the parties first clashed in a two day trial before Arnold J (as he then was). It was in <a class=link href=https://www.bailii.org/ew/cases/EWHC/Patents/2017/13.html target=_blank rel=noopener><strong>that judgment</strong></a>, delivered in January 2017, that the Judge referred the question that <a class=link href=https://www.bailii.org/ew/cases/EWHC/Patents/2012/2545.html target=_blank rel=noopener><strong>he previously referred</strong></a> in <em>Actavis v Sanofi</em> to the Court of Justice of the European Union (<strong>CJEU</strong>).Â  The reference asked:</p><blockquote><p>&ldquo;What are the criteria for deciding whether &rsquo;the product is protected by a basic patent in force&rsquo; in Article 3(a) of the SPC Regulation?&rdquo;</p></blockquote><p>The Judge, as he said at [96], was hoping that the CJEU would &ldquo;<em>provide a clear answer this time</em>&rdquo; as to what Article 3(a) required.Â  Did it require merely that the product fall within at least one claim of the basic patent applying the Extent of Protection Rules (i.e. Article 69 of the European Patent Convention and the accompanying Protocol), or did it require something stricter?Â  In his reference, the Judge trotted through the English court&rsquo;s and CJEU&rsquo;s case law Article 3(a) - <em>Takeda</em>, <em><a class=link href="https://www.bailii.org/cgi-bin/redirect.cgi?path=/eu/cases/EUECJ/1999/C39297.html" target=_blank rel=noopener><strong>Farmitalia</strong></a></em>,Â <em>Daiichi,</em>Â <em>Yeda</em>,Â _Medeva (_and its progeny),Â <em>Actavis v Sanofi</em>, <em><a class=link href=https://www.bailii.org/eu/cases/EUECJ/2013/C49312.html target=_blank rel=noopener><strong>Eli Lilly v HGS</strong></a></em>, <em><a class=link href=https://www.bailii.org/eu/cases/EUECJ/2015/C57713.html target=_blank rel=noopener><strong>Actavis v Boehringer,</strong></a></em> - and found that it was clear that something more was required, but what that &ldquo;<em>something</em>&rdquo; was was not clear.Â Â </p><p>His view, expressed at [97], was to embrace the &ldquo;<em>embodies the inventive advance</em>&rdquo; test.Â  He explained:Â Â </p><blockquote><p>&ldquo;&mldr;the answer is that the product must infringe because it contains an active ingredient, or a combination of active ingredients, which embodies the inventive advance (or technical contribution) of the basic patent. Where the product is a combination of active ingredients, the combination, as distinct from one of them, must embody the inventive advance of the basic patent. Thus in a case such as the present, where the inventive advance of the Patent consists generally of the compounds of formulae (1) and (1a), including specifically [tenofovir disoproxil (<strong>TD</strong>)],Â a medicinal product whose active ingredient is TD is protected by the Patent within the meaning of Article 3(a) because it embodies the inventive advance of the Patent. A medicinal product whose active ingredients are TD and another therapeutic agent such as emtricitabine in combination is not protected by the Patent within the meaning of Article 3(a) because the combination, as distinct from TD, does not embody the inventive advance of the Patent. This is not a question of the wording of the claims of the basic patent, which as discussed above can be manipulated by the patent attorney who drafts it, but of its substance. By contrast, if Gilead (or another inventor) were to obtain a patent for an invention consisting of a combination of TD and substance X which surprisingly had a synergistic effect in treating HIV, then a medicinal product whose active ingredients were TD and X would be protected by that patent since it would embody the inventive advance of that patent. In my view, this interpretation of Article 3(a) would accord with the object of the SPC Regulation, which is to encourage invention in the field of medicinal products by compensating inventors for the delay in exploiting their inventions due to the need to obtain regulatory approval, and not to confer unjustified monopolies.&rdquo;</p></blockquote><p>So thus, <em>Case C-121/17</em> was born.Â  An Opinion from Advocate General Wathelet followed.Â  The AG dismissed the &ldquo;inventive advance&rdquo; approach as being one that would invite confusion, but laid down another test that confirmed &ldquo;something more&rdquo; was needed at [81]-[82]:</p><blockquote><p>&ldquo;â€¦a product is protected by a patent within the meaning of Article 3(a) â€¦ if, on the priority date of the patent, it would have been obvious to a person skilled in the art that the active ingredient in question was specifically and precisely identifiable in the wording of the patent claims. In the case of a combination of active ingredients, each active ingredient must be specifically, precisely and individually identifiable in the wording of the patent claims.</p></blockquote><blockquote><p>The name of the active ingredient does not need to be referred to expressly in the claims, provided that the active ingredient is specifically and precisely identifiable as at the priority date of the patent.â€</p></blockquote><p>A short 18 months after the question was referred, on 25 July 2018 the <a class=link href=https://www.bailii.org/eu/cases/EUECJ/2018/C12117.html target=_blank rel=noopener><strong>CJEU delivered its decision</strong></a>.Â  It held:Â </p><blockquote><p>&ldquo;Article 3(a) of [the SPC Regulation] must be interpreted as meaning that a product composed of several active ingredients with a combined effect is &lsquo;protected by a basic patent in force&rsquo; within the meaning of that provision where, even if the combination of active ingredients of which that product is composed is not expressly mentioned in the claims of the basic patent, those claims relate necessarily and specifically to that combination. For that purpose, from the point of view of a person skilled in the art and on the basis of the prior art at the filing date or priority date of the basic patent:</p></blockquote><blockquote><p>â€“Â  Â  Â  Â  Â the combination of those active ingredients must necessarily, in the light of the description and drawings of that patent, fall under the invention covered by that patent, and<br>â€“Â  Â  Â  Â  Â each of those active ingredients must be specifically identifiable, in the light of all the information disclosed by that patent.&rdquo;</p></blockquote><p>A dog-eared copy of this decision with multi-color highlights, scrawls and underlined exclamation marks thereafter appeared on the AmeriKat&rsquo;s bulletin board.Â  &ldquo;<em>Necessarily and specifically&rdquo;</em>.Â  The AmeriKat was necessarily annoyed by the CJEU&rsquo;s decision, and specifically because it provided yet another test (comprised of two parts) to mosaic into the litany of Article 3(a) case law.Â  Sure enough, like asteroids colliding in space, national courts who subsequently applied the CJEU&rsquo;s decisionÂ <a class=link href=http://ipkitten.blogspot.com/2019/04/fordham-27-report-12-spcs.html target=_blank rel=noopener>started to spiral off</a> in different directions.Â  Â Â </p><p>Back on the terra firma of the Patents Court, Mr Justice Arnold (as he then was) was asked by Teva et al to provide his judgment in light of the CJEU&rsquo;s decision.Â  On 18 September 2018, the Judge held the SPC was invalid.Â  The first part of the CJEU&rsquo;s test, he said, was that:</p><blockquote><p>&ldquo;&mldr;from the point of view of a person skilled in the art and on the basis of the prior art at the priority date, the combination of active ingredients must necessarily, in the light of the description and drawings of the patent, fall under the invention covered by that patent. As explained above, this is not a simple extent of protection test. Rather, the combination must be one that the skilled person would understand, on the basis of the description and drawings and their common general knowledge, to embody the technical contribution made by the patent.&rdquo;</p></blockquote><p>Gilead&rsquo;s SPC failed this part.Â  The Judge held that the &lsquo;894 Patent said nothing aboutÂ tenofovir disoproxil and emtricitabine being combined to treat HIV; emtricitabine is not even mentioned.Â  There was thus no basis for the skilled person to understand that the combination embodies the technical contribution of the &lsquo;894 Patent.Â  Tenofovir disoproxil might be the technical contribution, but not the combination.Â Â </p><p>The second part of the CJEU&rsquo;s test was that:Â </p><blockquote><p>&ldquo;&mldr;from the point of view of a person skilled in the art and on the basis of the prior art at the priority date, each of the active ingredients must be specifically identifiable, in the light of all the information disclosed by the patent. "</p></blockquote><p>Gilead&rsquo;s SPC failed this second part of the test.Â  Although tenofovir disoproxil was specifically identifiable, emtricitabine was not.Â  Emtricitabine was not mentioned by the &lsquo;894 Patent, was not a member of a specific class ofÂ  compounds mentioned by the &lsquo;894 Patent (either by reference to structure or activity) and, although known by the skilled person at the priority date, there was no evidence that it was either known or CGK to be &ldquo;effective&rdquo; in the treatment of HIV.Â Â </p><p>The Court concluded that this result accorded with the objective of the SPC Regulation in that Gilead has already obtained a marking authorization for the &ldquo;mono&rdquo; fumerate form ofÂ  tenfovir disoproxil less than 5 years after the &lsquo;894 Patent was filed - thus not suffering any regulatory delay in exploiting the patent.Â  The <a class=link href=https://www.bailii.org/ew/cases/EWHC/Patents/2018/2416.html target=_blank rel=noopener><strong>final sentences of the decision</strong></a> referred to Gilead&rsquo;s patent for the combination having been revoked by the Opposition Division and their appeal dismissed.Â  &ldquo;<em>Thus Gilead made no invention in devising the combination which warranted the grant of a patent, let alone a SPC</em>.&rdquo;</p><p><strong>The Court of Appeal</strong></p><p>So, Gilead appealed.Â  The Court of Appeal hearing was last Tuesday and the decision was handed down this morning.Â </p><p>Gilead argued that the test was an Extent of Protection test, subject only to the two provisos (i.e. the two part test) provided by the CJEU.Â  Gilead satisfied both parts of the test.Â  The first part was meant to exclude products where the claim was only to A, but was said to protect A+B.Â  Â The &lsquo;894 Patent did&rsquo;t fall into this camp as the claim referred to other therapeutic ingredients.Â  The secondÂ  part of the test was meant to &ldquo;stop the clock&rdquo; in what knowledge the skilled person could use to determine whether the ingredient was identifiable.Â  EmtricitabineÂ  was identifiable at the priority date, so Gilead satisfied that test.Â  Gilead argued that the judge reached these conclusions because he had actually applied the &ldquo;inventive advance&rdquo; or &ldquo;technical contribution&rdquo; test and had assessed the second part of the test by reference to CGK, despite the court having expressly ruled that all the prior art formed the relevant pool ofÂ  knowledge.Â  Teva argued that the judge using the &ldquo;technical contribution&rdquo; test was not objectionable - the AG found the test objectionable only insofar as it conflated SPC law with the tests for patentability and inventive step.Â  What the Judge was really asking was &ldquo;is the product the actual subject matter of the patent&rdquo;.Â Â </p><p>Lord Justice Floyd gave the decision of the Court of Appeal, with Lord Justice Dingemans and Lord Justice Lewison agreeing.Â  He kicks off [18] <a class=link href=http://v/ target=_blank rel=noopener><strong>by declaring</strong></a> that thereÂ </p><blockquote><p>&ldquo;is no doubt that the CJEU has struggled with getting across national courts its understanding of what is meant by a product being protected by a basic patent for the purposes of Article 3(a) of the SPC Regulation.&rdquo;</p></blockquote><p>Floyd LJ then provided an excellent summary of the crescendo of Article 3(a) case law to date, including the AG andÂ  CJEU decisions in the present case and pending cases.Â  This can be summarized as follows:</p><ul><li>extent of protection can be determined only in the light of non-EU rules that govern patents (<em>Farmitalia</em>)</li><li>no SPCs for productsÂ relating to active ingredients which are &ldquo;not specified [or identified] in the wording of the claims&rdquo; (<em>Medeva and progeny</em>)</li><li>whether a product is protected depends on (i) the application of Article 69 and the Protocol, not to rules relating to infringement; (ii) the claims play a key role; (iii) active ingredients not identified by the claims by any means (i.e. structural or functional) are not protected; (iv) a structural formula is not necessary, a functional formula will suffice; (v) must be possible to reach the conclusion on the basis of the claims, interpreted inter alia in the light of the description of the invention, that the claims relate, implicitly but necessarily and specifically, to the active ingredient in question; (vi) it is for the national court to determine the application of the test (<em>Eli Lilly v HGS</em>, as summarized and applied in <em>Sandoz v GD Searle</em>)</li><li>for products that are not expressly specified or identified in the claims, to be protected the products must &ldquo;relate, implicitly but necessarily and specifically, to the active ingredient in question&rdquo;Â </li><li>The &ldquo;core inventive advance&rdquo; of the patent does not apply and is of no relevance in the context of Article 3(a) (AGÂ  Wathelet and CJEU in <em>Teva v Gilead</em> and AG Hogan&rsquo;s Opinion in <em>Sandoz v Searle</em> and <em>Royalty Pharma</em>).Â  The court has &ldquo;definitely set its face against the introduction of such a test - be it a &ldquo;inventive advance&rdquo; orÂ  &ldquo;technical contribution of the patent&rdquo; test.Â  This is because the express mention of an active ingredient is enough (see [37] of CJEU in <em>Teva v Gilead</em>).Â Â </li></ul><p>The Court of Appeal <a class=link href="https://drive.google.com/file/d/0B_U9nV8-MjxrRUhVbGtXUGRoVDhkbzVpR2l2R0g3MGlKOGtz/view?usp=sharing" target=_blank rel=noopener><strong>then held</strong></a> that:</p><p>(1)Â  The first part of the <em>Teva v Gilead</em> test is just &ldquo;<em>a more elaborate exposition of the &rsquo;necessarily&rsquo; part of the first part of the Lilly v HGS test, i.e &ldquo;the claims relate&mldr;necessarily&mldr;to the active ingredient in question.</em>&rdquo;Â Â </p><p>(2)Â  For a combination product to be protected, the claim must require the presence of two compounds.Â  This is not a simple Extent of Protection test - it goes further in that it demands that the claim &ldquo;requires&rdquo; each component be present in the claim.Â </p><p>(3) Claim 27 refers to &ldquo;<em>other therapeutic ingredients&rdquo;</em> as expressly being optional. The convenience in claim drafting of making it optional, so as to avoid writing out separate claims, was not a good enough reason to find that the combination was protected.Â  Â  The wording of the claim making it optional means that it is not &ldquo;required&rdquo;.Â  Claim drafting is important in this area (citing <em>Actavis v Boehringer (C-577/13)</em>- although the AmeriKat takes issue with over-reliance on that case as being an Article 3(a) case&mldr;).Â Â </p><p>(4)Â  Although the CJEU did not hold that the word &ldquo;optionally&rdquo; was fatal to Gilead&rsquo;s case, it still drew attention to the word.Â  The role that &ldquo;optionally&rdquo; plays in this assessment is a matter for the national courts.Â Â </p><p>(5)Â  There is nothing in the &lsquo;894 Patent that suggests to the skilled person that Claim 27 &ldquo;<em>requires the presence of another ingredient.Â  Everything points the other way. The skilled person might well know from the common general knowledge that other anti-viral agents would be useful in practice in the treatment of HIV, but he would not therefore assume that the presence of such an agent was required by the claim.</em>&rdquo;Â Â </p><p>(6) The breadth of Claim 27 is a factor.Â  The claim is not limited to a pharmaceutical composition containingÂ tenofovir disoproxil for the treatment of HIV, nor is the phrase &ldquo;<em>other therapeutic ingredients</em>&rdquo; limited to anti-viral agents either.Â  Claim breadth is another reason for not reading a requirement for the presence of a second anti-viral agent into Claim 27.Â  At [83] the Court ofÂ  Appeal <a class=link href="https://drive.google.com/file/d/0B_U9nV8-MjxrRUhVbGtXUGRoVDhkbzVpR2l2R0g3MGlKOGtz/view?usp=sharing" target=_blank rel=noopener><strong>continues</strong></a>:</p><blockquote><p>&ldquo;To put it another way, drawing on paragraph [48] of the courtâ€™s judgment, there is no basis for the skilled person to conclude that â€œthe product [i.e. TD plus another therapeutic ingredient] is specified as required for the solution of the technical problem disclosed by the patentâ€.&rdquo;</p></blockquote><p>(7) Wading into the second-part of the test presents difficult questions of who knew what, when and by what means (i.e. all prior art or CGK?) and is unnecessary, given the failure under the first-part of the test (see [85]). Floyd LJ explained that he &ldquo;<em>would prefer to leave those issues to a case in which their resolution affected the result</em>".Â  However, importantly, he <a class=link href="https://drive.google.com/file/d/0B_U9nV8-MjxrRUhVbGtXUGRoVDhkbzVpR2l2R0g3MGlKOGtz/view?usp=sharing" target=_blank rel=noopener><strong>said</strong> t</a>hat:</p><blockquote><p>&ldquo;I would only add that I would not wish to endorse the view, implicit in the judgeâ€™s paragraph [39], that if emtricitabine was otherwise sufficiently identified, it would be necessary to show that it was known at the priority date to be an effective agent for the treatment of HIV in humans, or approved for such use, or that these facts were by then, common general knowledge. Given that none of this was known for [tenofovir disoproxil] at the priority date, it may be that this is to impose too high a standard.&rdquo;</p></blockquote><p><strong>Comment</strong></p><p>According to the Court ofÂ  Appeal, patent claims apparently cannot be the <a class=link href=https://en.wikibooks.org/wiki/Muggles%27_Guide_to_Harry_Potter/Places/Room_of_Requirement target=_blank rel=noopener>Harry Potter-style &ldquo;Room of Requirement&rdquo;</a> when it comes to satisfying Article 3(a) of the SPC Regulation.Â  The second active ingredient cannot just appear in the room if you need it, if it wasn&rsquo;t there when you first walked in.Â  But is that or, more accurately, should that be right when given the constraints on claim drafting and ticking clocks in a first-to-file system?Â </p><p>There still seems to be a tension between saying the SPC confers the &ldquo;<em>same rights</em>&rdquo; as under the patent under Article 5, but then saying they are also &ldquo;limited&rdquo;.Â  The only form of statutory limitation is that under Article 4 (to which Article 5 is subject), but that limitation is by reference to the product subject to the SPC.Â  If the patent protects A+B, then the SPC should protect A+B if the product subject to the MA is A+B.Â  However, the case law says that although the patent might protect A+B, if B is not &ldquo;required&rdquo; by the claims then an SPC cannot protectÂ  A+B.Â  So the SPC is not &ldquo;<em>conferring the same rights</em>&rdquo; as that of the patent (assuming &ldquo;rights&rdquo; and &ldquo;protection&rdquo; are the same thing&mldr;).Â  This is consistent with the &ldquo;something more&rdquo; that the case law of the CJEU and of the Patents Court keeps referring to.Â  The &ldquo;something more&rdquo; is actually a limitation, contrary to Article 5.Â  Of course, one would rightly argue that the logic of some of the above is essentially an infringement test by the backdoor, which has been expressly rejected.Â  _MedevaÂ _at [25] also that states that it follows from Article 5 &ldquo;<em>that Article 3(a) of the regulation precludes the grant of a SPC relating to active ingredients which are not specified in the wording of the claims of the basic patent</em>".Â  But, like Lord Justice Arnold, the AmeriKat has never understood how &ldquo;<em>it follows</em>&rdquo;, unless you misunderstand patent law. But maybe that is the point&mldr;</p><p>But while the AmeriKat rustles around with this ball of yarn until she tires herself out, in-house patent attorneys will - subject to an appeal to the Supreme Court - likely be considering how to carve around the Court of Appeal&rsquo;s directions on claim drafting, &ldquo;<em>optionally</em>&rdquo; language, unity of invention and filing in time before the clinical trials are public.Â Â </p><p>So there you have it.Â  Happy holidays to all you SPC-lovers out there - a meaty little judgment for you to get your teeth into with your holiday champagne - the AmeriKat hopes it is a big bottle&mldr;</p></section><footer class=article-footer><section class=article-copyright><svg xmlns="http://www.w3.org/2000/svg" class="icon icon-tabler icon-tabler-copyright" width="24" height="24" viewBox="0 0 24 24" stroke-width="2" stroke="currentcolor" fill="none" stroke-linecap="round" stroke-linejoin="round"><path stroke="none" d="M0 0h24v24H0z"/><circle cx="12" cy="12" r="9"/><path d="M14.5 9a3.5 4 0 100 6"/></svg><span>Licensed under CC BY-NC-SA 4.0</span></section></footer></article><footer class=site-footer><script async src="https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js?client=ca-pub-3987358164777632" crossorigin=anonymous></script>
<script data-name=BMC-Widget src=https://cdn.buymeacoffee.com/widget/1.0.0/prod/widget.prod.min.js data-id=0x000216 data-description=coffee! data-message=coffee! data-color=#FF813F data-position=right data-x_margin=28 data-y_margin=18></script></footer><div class=pswp tabindex=-1 role=dialog aria-hidden=true><div class=pswp__bg></div><div class=pswp__scroll-wrap><div class=pswp__container><div class=pswp__item></div><div class=pswp__item></div><div class=pswp__item></div></div><div class="pswp__ui pswp__ui--hidden"><div class=pswp__top-bar><div class=pswp__counter></div><button class="pswp__button pswp__button--close" title="Close (Esc)"></button>
<button class="pswp__button pswp__button--share" title=Share></button>
<button class="pswp__button pswp__button--fs" title="Toggle fullscreen"></button>
<button class="pswp__button pswp__button--zoom" title="Zoom in/out"></button><div class=pswp__preloader><div class=pswp__preloader__icn><div class=pswp__preloader__cut><div class=pswp__preloader__donut></div></div></div></div></div><div class="pswp__share-modal pswp__share-modal--hidden pswp__single-tap"><div class=pswp__share-tooltip></div></div><button class="pswp__button pswp__button--arrow--left" title="Previous (arrow left)"></button>
<button class="pswp__button pswp__button--arrow--right" title="Next (arrow right)"></button><div class=pswp__caption><div class=pswp__caption__center></div></div></div></div></div><script src=https://cdn.jsdelivr.net/npm/photoswipe@4.1.3/dist/photoswipe.min.js integrity="sha256-ePwmChbbvXbsO02lbM3HoHbSHTHFAeChekF1xKJdleo=" crossorigin=anonymous defer></script><script src=https://cdn.jsdelivr.net/npm/photoswipe@4.1.3/dist/photoswipe-ui-default.min.js integrity="sha256-UKkzOn/w1mBxRmLLGrSeyB4e1xbrp4xylgAWb3M42pU=" crossorigin=anonymous defer></script><link rel=stylesheet href=https://cdn.jsdelivr.net/npm/photoswipe@4.1.3/dist/default-skin/default-skin.css integrity="sha256-c0uckgykQ9v5k+IqViZOZKc47Jn7KQil4/MP3ySA3F8=" crossorigin=anonymous><link rel=stylesheet href=https://cdn.jsdelivr.net/npm/photoswipe@4.1.3/dist/photoswipe.css integrity="sha256-SBLU4vv6CA6lHsZ1XyTdhyjJxCjPif/TRkjnsyGAGnE=" crossorigin=anonymous></main></div><script src=https://cdn.jsdelivr.net/npm/node-vibrant@3.1.5/dist/vibrant.min.js integrity="sha256-5NovOZc4iwiAWTYIFiIM7DxKUXKWvpVEuMEPLzcm5/g=" crossorigin=anonymous></script><script type=text/javascript src=/ts/main.js defer></script>
<script>(function(){const e=document.createElement("link");e.href="https://fonts.googleapis.com/css2?family=Lato:wght@300;400;700&display=swap",e.type="text/css",e.rel="stylesheet",document.head.appendChild(e)})()</script></body></html>